SRRK logo

SRRK Scholar Rock Holding Corporation

NASDAQ Global Select · Biotechnology · Healthcare

$48.13
-2.24 (-4.45%)

Scholar Rock Holding Corporation is a biopharmaceutical firm dedicated to discovering and advancing treatments for severe medical conditions by targeting the crucial role of protein growth factor signaling. Their lead therapeutic candidate, Apitegromab, an agent designed to inhibit the activation of latent myostatin, has successfully concluded Phase 3 clinical trials for spinal muscular atrophy (S…

Market Cap: $5.87Bscholarrock.com

Price

$52.92+14.30%
$43.80$48.51$53.23$57.94
Apr 29Aug 7

Social Signal Score

59
5d
—
30d
62
4 mentions
+0.0%
60d
62
4 mentions
+0.0%
90d
54
14 mentions
+0.0%
news: 9 · rss: 5

Analyst Ratings

15 analysts
Buyconsensus
Strong Buy 1Buy 12Hold 2Sell 0Strong Sell 0
Avg price target$71.3+48.1%
Low $58Median $71High $84
Current Consensus

Revenue

$570.0K
$0.00$11.06M$22.13M$33.19M
Mar 2017Sep 2026

Analyst Estimates

FY2025
$-3.44
$-3.56–$-3.24
10 analysts
FY2026
$-3.22
$-3.81–$-1.85
12 analysts
FY2027
$-2.57
$-3.06–$-2.18
14 analysts

Consensus estimates, not results. Via Financial Modeling Prep.

Company Profile

CEO
David L. Hallal
Sector
Healthcare
Industry
Biotechnology
Employees
289
Beta
0.62
Country
US
Piotroski score
3 / 9 (Weak)
Altman Z-score
5.60
scholarrock.com